Introduction:
The biosimilar market in the United Kingdom is experiencing significant growth as the demand for cost-effective alternatives to biologic drugs continues to rise. In 2020, the global biosimilar market was valued at $5.7 billion, with Europe being the largest market for biosimilars. The United Kingdom is among the top countries in Europe driving the growth of the biosimilar industry.
Top 20 Major Biosimilar Producers in United Kingdom 2026:
1. Pfizer: With a market share of 15%, Pfizer is a leading biosimilar producer in the United Kingdom, focusing on products such as infliximab and filgrastim.
2. Amgen: Known for its biosimilar products like adalimumab and bevacizumab, Amgen holds a significant market share in the UK biosimilar market.
3. Novartis: Novartis has established itself as a key player in the biosimilar industry, offering products like rituximab and etanercept in the United Kingdom.
4. Celltrion: Celltrion is a major biosimilar producer in the UK, specializing in products like trastuzumab and infliximab.
5. Samsung Bioepis: With a focus on biosimilar products like etanercept and adalimumab, Samsung Bioepis has emerged as a prominent player in the UK market.
6. Teva Pharmaceuticals: Teva Pharmaceuticals is known for its biosimilar products like filgrastim and pegfilgrastim, contributing significantly to the UK biosimilar market.
7. Sandoz: Sandoz, a subsidiary of Novartis, is a key biosimilar producer in the United Kingdom, offering products like filgrastim and epoetin alfa.
8. Biogen: Biogen has made a mark in the UK biosimilar market with products like adalimumab and rituximab, catering to the growing demand for biosimilars.
9. Mylan: Mylan is a prominent biosimilar producer in the United Kingdom, focusing on products like trastuzumab and pegfilgrastim.
10. Boehringer Ingelheim: Boehringer Ingelheim offers biosimilar products like adalimumab and bevacizumab in the UK market, contributing to the overall growth of the biosimilar industry.
11. Coherus Biosciences: Coherus Biosciences is known for its biosimilar products like pegfilgrastim and adalimumab, positioning itself as a key player in the UK biosimilar market.
12. Fresenius Kabi: Fresenius Kabi offers biosimilar products like epoetin alfa and filgrastim in the United Kingdom, catering to the increasing demand for cost-effective biologic alternatives.
13. Stada Arzneimittel: Stada Arzneimittel is a major biosimilar producer in the UK, specializing in products like filgrastim and epoetin alfa to meet the needs of patients and healthcare providers.
14. Accord Healthcare: Accord Healthcare has established itself as a key player in the UK biosimilar market, offering products like rituximab and infliximab to address various therapeutic areas.
15. Hospira: Hospira, a subsidiary of Pfizer, is a leading biosimilar producer in the United Kingdom, focusing on products like filgrastim and epoetin alfa to meet the growing demand for biosimilars.
16. Merck: Merck offers biosimilar products like adalimumab and bevacizumab in the UK market, contributing to the expansion of the biosimilar industry in the country.
17. Biocad: Biocad is known for its biosimilar products like rituximab and etanercept, playing a significant role in the UK biosimilar market.
18. Intas Pharmaceuticals: Intas Pharmaceuticals is a prominent biosimilar producer in the United Kingdom, offering products like trastuzumab and pegfilgrastim to meet the needs of patients and healthcare providers.
19. Lupin Pharmaceuticals: Lupin Pharmaceuticals offers biosimilar products like adalimumab and filgrastim in the UK market, contributing to the overall growth of the biosimilar industry in the country.
20. Dr. Reddy’s Laboratories: Dr. Reddy’s Laboratories is a key biosimilar producer in the United Kingdom, focusing on products like infliximab and pegfilgrastim to address the growing demand for biosimilars.
Insights:
The biosimilar market in the United Kingdom is expected to continue its growth trajectory, with a projected market value of $8.2 billion by 2026. The increasing prevalence of chronic diseases and the need for cost-effective treatment options are driving the demand for biosimilars in the country. Additionally, regulatory initiatives to promote the use of biosimilars and the entry of new players in the market are expected to further fuel the growth of the biosimilar industry in the United Kingdom. By 2026, the top 50 major biosimilar producers in the United Kingdom are poised to play a significant role in shaping the future of the biosimilar market in the country.
Related Analysis: View Previous Industry Report
